TKI resistant NSCLC patients exhibit aberrant EGFR and cMET signaling as well as elevated vascular endothelial growth factor (VEGF) receptor pathway activity which is a critical driver of solid tumor angiogenesis (19). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.